Terms: = Germ cell tumor AND MSH2, COCA1, 4436, ENSG00000095002, HNPCC, FCC1, HNPCC1, P43246 AND Prognosis
37 results:
1. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
2. Colorectal neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasm: Prognostic factors and PD-L1 expression.
Ho YH; Hsu CY; Yau Li AF; Liang WY
Hum Pathol; 2024 Mar; 145():80-85. PubMed ID: 38423221
[TBL] [Abstract] [Full Text] [Related]
3. SOMATIC DEFICIENT MISMATCH REPAIR ASSESSED BY IMMUNOHISTOCHEMISTRY AND CLINICAL FEATURES IN BRAZILIAN GLIOBLASTOMA PATIENTS.
Yamada CAF; Malheiros SMF; Do Amaral LLF; Lancellotti CLP
Exp Oncol; 2023 Dec; 45(3):297-311. PubMed ID: 38186025
[TBL] [Abstract] [Full Text] [Related]
4. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
5. Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
Wu J; Jin S; Gu C; Wei Y; Zhu Y; Necchi A; Shariat SF; Pan J; Gan H; Dai B; Zhang H; Shi G; Zhu Y; Shen Y; Zhu Y; Ye D
Cell Rep Med; 2023 Jan; 4(1):100883. PubMed ID: 36630951
[TBL] [Abstract] [Full Text] [Related]
6. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
Li K; Liu Y; Han J; Gui J; Zhang X
Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
[TBL] [Abstract] [Full Text] [Related]
7. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract] [Full Text] [Related]
8. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and prognosis.
Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
[TBL] [Abstract] [Full Text] [Related]
9. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
[TBL] [Abstract] [Full Text] [Related]
10. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.
Brown LC; Halabi S; Somarelli JA; Humeniuk M; Wu Y; Oyekunle T; Howard L; Huang J; Anand M; Davies C; Patel P; Staats J; Weinhold KJ; Harrison MR; Zhang T; George DJ; Armstrong AJ
Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):762-769. PubMed ID: 35292724
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Yang RR; Li KK; Zhang ZY; Chan AK; Wang WW; Chan DT; Li WC; Liu XZ; Li FC; Chen H; Ng HK; Mao Y; Shi ZF
Clin Neurol Neurosurg; 2021 Sep; 208():106882. PubMed ID: 34428613
[TBL] [Abstract] [Full Text] [Related]
12. Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries.
Rocha CRR; Reily Rocha A; Molina Silva M; Rodrigues Gomes L; Teatin Latancia M; Andrade Tomaz M; de Souza I; Karolynne Seregni Monteiro L; Menck CFM
Cells; 2020 Dec; 9(12):. PubMed ID: 33271924
[TBL] [Abstract] [Full Text] [Related]
13. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract] [Full Text] [Related]
14. Homogeneous MMR Deficiency Throughout the Entire tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas.
Fraune C; Simon R; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Büscheck F; Amin T; Viol F; Fehrle W; Dum D; Höflmayer D; Burandt E; Clauditz TS; Perez D; Izbicki J; Wilczak W; Sauter G; Steurer S; Schrader J
Endocr Pathol; 2020 Jun; 31(2):182-189. PubMed ID: 32144630
[TBL] [Abstract] [Full Text] [Related]
15. A novel DNA damage response signature of IDH-mutant grade II and grade III astrocytoma at transcriptional level.
Liu Q; Wang K; Huang R; Tong X; Jiang T; Wang J; Yang P
J Cancer Res Clin Oncol; 2020 Mar; 146(3):579-591. PubMed ID: 32060643
[TBL] [Abstract] [Full Text] [Related]
16. Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 cells treated with Temozolomide.
Guo J; Yi GZ; Liu Z; Sun X; Yang R; Guo M; Li Y; Li K; Li K; Wang X; Song H; Qi S; Huang G; Liu Y
Cell Biochem Funct; 2020 Mar; 38(2):185-194. PubMed ID: 31833081
[TBL] [Abstract] [Full Text] [Related]
17. Microsatellite Instability in Glioblastoma: Is It Really Relevant in tumor prognosis?
Tepeoglu M; Borcek P; Ozen O; Altinors N
Turk Neurosurg; 2019; 29(5):778-784. PubMed ID: 31529454
[TBL] [Abstract] [Full Text] [Related]
18. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract] [Full Text] [Related]
19. Differential Proteomic Analysis between Small cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
Fujii K; Miyata Y; Takahashi I; Koizumi H; Saji H; Hoshikawa M; Takagi M; Nishimura T; Nakamura H
Proteomics Clin Appl; 2018 Nov; 12(6):e1800015. PubMed ID: 29888431
[TBL] [Abstract] [Full Text] [Related]
20. G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity.
Yang CA; Huang HY; Lin CL; Chang JG
J Neurooncol; 2018 Sep; 139(3):661-670. PubMed ID: 29845423
[TBL] [Abstract] [Full Text] [Related]
[Next]
